Avalon Investment & Advisory acquired a new position in Halozyme Therapeutics, Inc. ( NASDAQ:HALO – Get Rating ) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,725 shares of the biopharmaceutical company's stock, valued at approximately $269,000. Several other institutional investors have also bought and sold shares of the stock. Dupont Capital Management Corp lifted its holdings in Halozyme Therapeutics by 3.

https://www.dailypolitical.com/2023/06/03/4725-shares-in-halozyme-therapeutics-inc-nasdaqhalo-purchased-by-avalon-investment-advisory.html

#dailypolitical